YC-1 Inhibits HIF-1 Expression in Prostate Cancer Cells: Contribution of Akt/NF-κB Signaling to HIF-1α Accumulation During Hypoxia

H-L Sun,Y-N Liu,Y-T Huang,S-L Pan,D-Y Huang,J-H Guh,F-Y Lee,S-C Kuo,C-M Teng

DOI: https://doi.org/10.1038/sj.onc.1210169

IF: 8.756

2007-01-01

Oncogene

Abstract:Hypoxia-inducible factor 1 (HIF-1), a transcription factor that is critical for tumor adaptation to microenvironmental stimuli, represents an attractive chemotherapeutic target. YC-1 is a novel antitumor agent that inhibits HIF-1 through previously unexplained mechanisms. In the present study, YC-1 was found to prevent HIF-1 α and HIF-1 β accumulation in response to hypoxia or mitogen treatment in PC-3 prostate cancer cells. Neither HIF-1 α protein half-life nor mRNA level was affected by YC-1. However, YC-1 was found to suppress the PI3K/Akt/mTOR/4E-BP pathway, which serves to regulate HIF-1 α expression at the translational step. We demonstrated that YC-1 also inhibited hypoxia-induced activation of nuclear factor (NF)- κ B, a downstream target of Akt. Two modulators of the Akt/NF- κ B pathway, caffeic acid phenethyl ester and evodiamine, were observed to decrease HIF-1 α expression. Additionally, overexpression of NF- κ B partly reversed the ability of wortmannin to inhibit HIF-1 α -dependent transcriptional activity, suggesting that NF- κ B contributes to Akt-mediated HIF-1 α accumulation during hypoxia. Overall, we identify a potential molecular mechanism whereby YC-1 serves to reduce HIF-1 expression.